Aurelio Castrellon
- Oncology top 10%
- Pulmonary and Respiratory Medicine top 5%
- Cancer Research top 10%
- Genetics top 10%
- Molecular Biology
- Co-authors
- Stefan GlückA. MoriRichard S. FinnVéronique DièrasDongrui R. LuAnil A. JoyNadia HarbeckKaren A. Gelmon
- Topics
- Advanced Breast Cancer Therapies (13 papers)HER2/EGFR in Cancer Research (12 papers)Cancer Treatment and Pharmacology (6 papers)
- Partner nations
- United StatesCanadaItaly
In The Last Decade
Aurelio Castrellon
31 papers receiving 641 citations
Hit Papers
Peers
Comparison fields: 5 of 69
- Oncology 429
- Pulmonary and Respiratory Medicine 392
- Cancer Research 210
- Genetics 125
- Molecular Biology 102
Countries citing papers authored by Aurelio Castrellon
This map shows the geographic impact of Aurelio Castrellon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aurelio Castrellon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aurelio Castrellon more than expected).
Fields of papers citing papers by Aurelio Castrellon
This network shows the impact of papers produced by Aurelio Castrellon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aurelio Castrellon. The network helps show where Aurelio Castrellon may publish in the future.
Co-authorship network of co-authors of Aurelio Castrellon
This figure shows the co-authorship network connecting the top 25 collaborators of Aurelio Castrellon. A scholar is included among the top collaborators of Aurelio Castrellon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aurelio Castrellon. Aurelio Castrellon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 7 | |
| 2 | 6 | |
| 3 | Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-upbreakdown → | 286 |
| 4 | 24 | |
| 5 | 25 | |
| 6 | 11 | |
| 7 | 1 | |
| 8 | Initial Response to Therapy with Fulvestrant and Cyclin-Dependent Kinase 4/6 Inhibitor in a Male with Stage IV Breast Cancer | 1 |
| 9 | 1 | |
| 10 | 2 | |
| 11 | 23 | |
| 12 | 28 | |
| 13 | 1 | |
| 14 | 14 | |
| 15 | 68 | |
| 16 | 16 | |
| 17 | 5 | |
| 18 | Adjuvant therapy for HER2 positive breast cancer: are anthracyclines still necessary? | 5 |
| 19 | 4 | |
| 20 | 20 |
About Aurelio Castrellon
Aurelio Castrellon is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine, having authored 34 papers that have together received 655 indexed citations. Recurring topics across this work include Advanced Breast Cancer Therapies (13 papers), HER2/EGFR in Cancer Research (12 papers) and Cancer Treatment and Pharmacology (6 papers). The work is most often cited by research in Oncology (429 citations), Cancer Research (210 citations) and Pulmonary and Respiratory Medicine (392 citations). Aurelio Castrellon has collaborated with scholars based in United States, Canada and Italy. Frequent co-authors include Stefan Glück, A. Mori, Richard S. Finn, Véronique Dièras, Dongrui R. Lu, Anil A. Joy, Nadia Harbeck, Karen A. Gelmon, Hope S. Rugo and Dennis J. Slamon. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research and International Journal of Molecular Sciences.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.